Skip to main content
TipRanks
Go Ultimate75% OFF

Crescent Biopharma (CBIO) AI Stock Analysis

1,027 Followers
CBIO

Crescent Biopharma

(NASDAQ:CBIO)

Select Model
Rating:50Neutral
Price Target:$14.00▼(-1.06% Downside)
Action:reiterated
Date:11/14/26

The score is held back primarily by substantial ongoing losses and significant cash burn despite improving revenue and very high gross margins. Technically, the stock shows neutral momentum but remains below key longer-term moving averages. Valuation support is limited by negative earnings, while recent positive pipeline milestones modestly offset the risk profile.

Positive Factors
Revenue Growth and Gross MarginRevenue growth shows that CBIO is expanding its current commercial base, while the exceptionally high gross margin indicates limited direct cost burden on reported revenue. If sustained, this profile could provide operating leverage when development spending becomes more controlled.
Negative Factors
Severe Operating LossesLosses are vastly larger than current revenue, showing that CBIO’s cost base remains disconnected from its present commercial scale. This weak profitability reduces internal funding capacity and means future progress depends on substantial improvement in operating efficiency or additional financing.

Crescent Biopharma (CBIO) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%125%CBIO+8.85%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$525.59M
Dividend Yield
―
Average Volume (3M)
348.19K
Price to Earnings (P/E)
-2.0
Beta (1Y)
1.54
Revenue Growth
―
EPS Growth
67.56%
Country
US
Employees
44
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Crescent Biopharma Business Overview & Revenue Model

Company Description

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 an...

Crescent Biopharma Earnings Call Summary

Earnings Call Date:May 06, 2024(Q1-2024)|% Change Since:-92.27%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentNeutral

The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.

Positive Updates

Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.

Negative Updates

Phase III Study Did Not Meet Primary Endpoint
The pivotal Phase III study of uproleselan did not achieve a statistically significant improvement in overall survival in the intent-to-treat population.

Company Guidance

During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.

Crescent Biopharma Financial Statement Overview

Summary

Revenue is growing (+26.2% TTM) with exceptionally high gross margin (~99.6%) and very low leverage (debt-to-equity ~0.009), but results are dominated by large operating and net losses (net margin about -1,174%) and heavy cash burn (TTM FCF -$162.4M), keeping overall financial quality constrained despite solid capitalization.

Income Statement

24Negative

Balance Sheet

72Positive

Cash Flow

29Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue15.00M10.84M010.00K75.00K1.16M
Gross Profit14.93M10.84M010.00K75.00K1.16M
EBITDA-178.17M-149.67M-44.17M-39.12M-47.20M-63.18M
Net Income-176.09M-153.94M-48.52M-36.90M-46.69M-63.43M
Balance Sheet
Total Assets299.50M240.29M35.62M45.32M51.81M94.35M
Cash, Cash Equivalents and Short-Term Investments289.36M213.19M34.77M41.79M47.87M90.25M
Total Debt2.46M1.64M37.48M808.40K918.55K1.92M
Total Liabilities25.22M37.28M51.10M6.90M8.88M12.74M
Stockholders Equity274.28M203.01M-15.48M38.41M42.93M81.60M
Cash Flow
Free Cash Flow-162.43M-144.45M-31.11M-34.90M-46.54M-57.50M
Operating Cash Flow-82.08M-71.53M-31.10M-34.88M-46.46M-57.49M
Investing Cash Flow-78.58M-72.92M20.03K-21.39K-84.19K-14.94K
Financing Cash Flow316.86M322.98M5,39828.82M4.16M10.72M

Crescent Biopharma Technical Analysis

Technical Analysis SentimentNeutral
Last Price14.15

Price Trends

50DMA14.80Negative
100DMA15.76Negative
200DMA15.95Negative

Market Momentum

MACD-0.03Negative
RSI52.34Neutral
STOCH67.82Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBIO, the sentiment is Neutral. The current price of 14.15 is above the 20-day moving average (MA) of 13.44, below the 50-day MA of 14.80, and below the 200-day MA of 15.95, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 67.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CBIO.

Crescent Biopharma Risk Analysis

Crescent Biopharma disclosed 69 risk factors in its most recent earnings report. Crescent Biopharma reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.Q2, 2026
2.Preferred directors elected by the holders of our Series A Preferred Shares have the ability to control or significantly influence all matters submitted to our board of directors for approval.Q4, 2025
3.We are governed by Cayman Islands law, and certain provisions of our Articles of Association have anti-takeover implications.Q4, 2025

Crescent Biopharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CGENCGEN66Neutral$198.93M5.4039.30%―999.97%―
OBIOOBIO60Neutral$570.61M-8.15-140.18%―1007.38%50.23%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CBIOCBIO50Neutral$550.37M-2.00-85.44%――67.56%
GUTSGUTS45Neutral$11.99M-0.16-1860.27%―-100.00%79.01%
FATEFATE42Neutral$155.61M-1.24-73.92%―-33.45%21.90%

* Healthcare Sector Average

Performance Comparison

0%100%200%CBIOCGENFATEOBIOGUTSACTUDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CBIOCrescent Biopharma, Inc.14.151.088.26%
CGENCompugen2.100.5132.08%
FATEFate Therapeutics Inc1.280.3131.55%
OBIOOrchestra Biomed Holdings, Inc.7.253.1275.54%
GUTSFractyl Health, Inc.0.90-16.26-94.74%
ACTUActuate Therapeutics, Inc.0.28-5.63-95.19%

Crescent Biopharma Corporate Events

Business Operations and StrategyProduct-Related Announcements

Crescent Biopharma advances oncology pipeline and ADC programs

Positive
Oct 15, 2026

On October 15, 2026, Crescent Biopharma reported progress across its oncology pipeline, highlighting completion of dose escalation and broad enrollment in the global Phase 1/2 ASCEND trial of CR-001 monotherapy, with initial safety, pharmacokinetic a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026